WCN26-6575 CHANGE IN SOLUBLE BIOMARKER LEVELS IN PATIENTS WITH IgA NEPHROPATHY: AN ANALYSIS OF THE PHASE 2 TRIAL OF RAVULIZUMAB (SANCTUARY)
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Publication details
- Journal / source
- Kidney International Reports
- Volume
- 11
- Issue
- 4
- Pages
- 104504–104504
- Publication date
- 25 March 2026
- Language
- EN